BR112019023260A2 - Fatores de crescimento de fibroblastos recombinantes modificados e seus usos terapêuticos - Google Patents
Fatores de crescimento de fibroblastos recombinantes modificados e seus usos terapêuticosInfo
- Publication number
- BR112019023260A2 BR112019023260A2 BR112019023260-5A BR112019023260A BR112019023260A2 BR 112019023260 A2 BR112019023260 A2 BR 112019023260A2 BR 112019023260 A BR112019023260 A BR 112019023260A BR 112019023260 A2 BR112019023260 A2 BR 112019023260A2
- Authority
- BR
- Brazil
- Prior art keywords
- fibroblast growth
- growth factors
- modified
- therapeutic uses
- modified recombinant
- Prior art date
Links
- 102000018233 Fibroblast Growth Factor Human genes 0.000 title abstract 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 1
- 229940126864 fibroblast growth factor Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
polipeptídeo relacionado a fatores de crescimento de fibroblastos recombinantes modificados, composição e seus usos. são descritos na presente invenção polipeptídeos de fator de crescimento de fibroblastos modificados (fgf), composições farmacêuticas e medicamentos que incluem esses polipeptídeos de fgf modificados, e métodos de uso desses polipeptídeos de fgf modificados para tratar ou prevenir condições que se beneficiam da administração de fgfs.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762502529P | 2017-05-05 | 2017-05-05 | |
US201762502540P | 2017-05-05 | 2017-05-05 | |
US62/502,529 | 2017-05-05 | ||
US62/502,540 | 2017-05-05 | ||
US201762584624P | 2017-11-10 | 2017-11-10 | |
US62/584,624 | 2017-11-10 | ||
PCT/US2018/031189 WO2018204847A2 (en) | 2017-05-05 | 2018-05-04 | Recombinant modified fibroblast growth factors and therapeutic uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019023260A2 true BR112019023260A2 (pt) | 2022-02-22 |
Family
ID=64016756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019023260-5A BR112019023260A2 (pt) | 2017-05-05 | 2018-05-04 | Fatores de crescimento de fibroblastos recombinantes modificados e seus usos terapêuticos |
Country Status (10)
Country | Link |
---|---|
US (2) | US11479591B2 (pt) |
EP (1) | EP3619324A4 (pt) |
JP (1) | JP2020518287A (pt) |
KR (1) | KR20200078425A (pt) |
CN (1) | CN111148755A (pt) |
AU (1) | AU2018261021A1 (pt) |
BR (1) | BR112019023260A2 (pt) |
CA (1) | CA3062473A1 (pt) |
MX (1) | MX2019013210A (pt) |
WO (1) | WO2018204847A2 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2019013210A (es) | 2017-05-05 | 2020-07-20 | Trefoil Therapeutics Inc | Factores de crecimiento recombinantes modificados de fibroblastos y usos terapéuticos de los mismos. |
US20230263050A1 (en) | 2020-06-26 | 2023-08-17 | Lt Materials Co., Ltd. | Heterocyclic compound and organic light-emitting device using same |
TW202310868A (zh) * | 2021-05-14 | 2023-03-16 | 美商克拉里斯生物醫療股份有限公司 | 用於治療眼睛疾病的生長因子組合物 |
CN113289005B (zh) * | 2021-07-06 | 2022-05-31 | 温州医科大学 | rhFGF-21在制备治疗干眼症药物中的应用 |
WO2023019218A1 (en) * | 2021-08-12 | 2023-02-16 | Trefoil Therapeutics, Inc. | Modified fibroblast growth factors for treating fibrotic diseases |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5552528A (en) * | 1986-03-03 | 1996-09-03 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bovine b-endothelial cell growth factor |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
GB2223496B (en) * | 1988-08-08 | 1992-05-27 | British Bio Technology | Synthetic gene encoding mature human acid fibroblast growth factor |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
GB9523946D0 (en) | 1995-11-23 | 1996-01-24 | Bayer Ag | Leukotriene antagonistic benzoic acid derivatives |
US20010006939A1 (en) * | 1997-10-03 | 2001-07-05 | Ralph W. Niven | Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions |
AU1628101A (en) | 1999-11-22 | 2001-06-04 | Millennium Pharmaceuticals, Inc. | Jaffa, a novel fibroblast growth factor family member and uses therefor |
AU8825601A (en) * | 2000-08-15 | 2002-02-25 | Phage Biotechnology Corp | A method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis |
US20050227929A1 (en) | 2003-11-13 | 2005-10-13 | Masferrer Jaime L | Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent |
US7790682B1 (en) | 2003-12-02 | 2010-09-07 | The Florida State University Research Foundation, Inc. | Engineered human acidic fibroblast growth factors and associated methods |
EA200601121A1 (ru) * | 2003-12-10 | 2006-10-27 | Эли Лилли Энд Компани | Мутеины фактора роста фибробластов 21 |
US7776825B1 (en) | 2006-11-09 | 2010-08-17 | Florida State University Research Foundation, Incorporated | Mutant polypeptides of fibroblast growth factor 1 |
US7659379B1 (en) | 2007-05-24 | 2010-02-09 | Florida State University Research Foundation, Inc. | Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency |
MX356129B (es) * | 2008-01-22 | 2018-05-16 | Araim Pharmaceuticals Inc | Peptidos y analogos de peptidos protectores de los tejidos para evitar y tratar padecimientos y desordenes asociados con daño de los tejidos. |
US8461111B2 (en) | 2009-05-20 | 2013-06-11 | Florida State University Research Foundation | Fibroblast growth factor mutants having improved functional half-life and methods of their use |
US20110224404A1 (en) | 2010-03-11 | 2011-09-15 | Florida State University Research Foundation | Method for development of a peptide building block useful for de novo protein design |
TWI593708B (zh) * | 2011-09-26 | 2017-08-01 | 諾華公司 | 治療代謝病症之融合蛋白質 |
US20150253308A1 (en) * | 2013-05-03 | 2015-09-10 | Orasis | Compositions and methods of treating glaucoma |
WO2015048188A2 (en) * | 2013-09-25 | 2015-04-02 | Trefoil Therapeutics, Llc | Modified fibroblast growth factors for the treatment of ocular disorders |
US9925241B2 (en) | 2013-10-21 | 2018-03-27 | Salk Institute For Biological Studies | Mutated fibroblast growth factor (FGF) 1 and methods of use |
WO2015198175A1 (en) | 2014-06-27 | 2015-12-30 | Florida State University Research Foundation, Inc. | Design of fgf-1 mutants to effectively eliminate reactive cysteine residues |
AU2016252423A1 (en) | 2015-04-20 | 2017-11-23 | Florida State University Research Foundation, Incorporated | Fibroblast growth factor (FGF) 1 with mutation in the heparin binding domain and methods of use to reduce blood glucose |
EP3285793A4 (en) * | 2015-04-20 | 2018-10-10 | Salk Institute for Biological Studies | Fibroblast growth factor (fgf) 1 mutants and methods of use to reduce blood glucose |
WO2017026156A1 (ja) * | 2015-08-13 | 2017-02-16 | 富士フイルム株式会社 | 多能性幹細胞の培養方法、培養容器の製造方法、培養容器、及び細胞培養用の足場材料 |
MX2019013210A (es) | 2017-05-05 | 2020-07-20 | Trefoil Therapeutics Inc | Factores de crecimiento recombinantes modificados de fibroblastos y usos terapéuticos de los mismos. |
-
2018
- 2018-05-04 MX MX2019013210A patent/MX2019013210A/es unknown
- 2018-05-04 KR KR1020197035895A patent/KR20200078425A/ko not_active Application Discontinuation
- 2018-05-04 US US16/611,182 patent/US11479591B2/en active Active
- 2018-05-04 BR BR112019023260-5A patent/BR112019023260A2/pt unknown
- 2018-05-04 EP EP18794391.5A patent/EP3619324A4/en active Pending
- 2018-05-04 JP JP2020511867A patent/JP2020518287A/ja active Pending
- 2018-05-04 CA CA3062473A patent/CA3062473A1/en active Pending
- 2018-05-04 AU AU2018261021A patent/AU2018261021A1/en active Pending
- 2018-05-04 WO PCT/US2018/031189 patent/WO2018204847A2/en active Application Filing
- 2018-05-04 CN CN201880044863.5A patent/CN111148755A/zh active Pending
-
2022
- 2022-09-07 US US17/939,238 patent/US20230130851A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2018204847A2 (en) | 2018-11-08 |
JP2020518287A (ja) | 2020-06-25 |
MX2019013210A (es) | 2020-07-20 |
RU2019139358A (ru) | 2021-06-07 |
EP3619324A4 (en) | 2020-12-30 |
CN111148755A (zh) | 2020-05-12 |
RU2019139358A3 (pt) | 2021-08-26 |
EP3619324A2 (en) | 2020-03-11 |
CA3062473A1 (en) | 2018-11-08 |
KR20200078425A (ko) | 2020-07-01 |
US11479591B2 (en) | 2022-10-25 |
AU2018261021A1 (en) | 2019-12-12 |
US20230130851A1 (en) | 2023-04-27 |
US20200190158A1 (en) | 2020-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019023260A2 (pt) | Fatores de crescimento de fibroblastos recombinantes modificados e seus usos terapêuticos | |
BR112019000528A2 (pt) | distribuição mediada por ve de conjugados de proteína de ligação-molécula pequena | |
BR112018004536A2 (pt) | peptídeos de endereçamento à cartilagem | |
ECSP14030742A (es) | Proteínas del factor 21 de crecimiento del fibroblasto | |
CO2019002609A2 (es) | Proteínas de unión recombinantes y sus usos | |
BR112017025108A2 (pt) | compostos seletivos de pyy e usos dos mesmos | |
AR116605A1 (es) | Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a) | |
BR112018001761A2 (pt) | uso de variantes de peptídeo natriurético tipo c para tratar a displasia esquelética | |
BR112018077457A2 (pt) | composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado | |
ECSP18073366A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
BR112021018506A2 (pt) | Terapia de combinação para tratamento do câncer | |
BR112019000692A8 (pt) | Moduladores de somatostatina e usos destes | |
BR112017019062A2 (pt) | conjugados de anticorpo-fármaco (adc) que se ligam a proteínas flt3 | |
PH12021550705A1 (en) | Stable semaglutide compositions and uses thereof | |
BR112019017393A8 (pt) | Composição farmacêutica de evolocumab e seu uso, kit, método para preparar polipeptídeo de ligação a pcsk9 e método para formular polipeptídeo terapêutico | |
BR112021006280A2 (pt) | terapias imunoablativas | |
CR20180184A (es) | Compuestos heteroarilo y su uso como fármacos terapéuticos | |
CO2021013677A2 (es) | Proceso para la fabricación de extractos bacterianos estables y su uso como fármacos | |
UY38069A (es) | Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico | |
BR112023006024A2 (pt) | Terapias de imuno-oncologia com conjugados de il-2 | |
CO2022007814A2 (es) | Ligandos de la pseudoquinasa tyk2 | |
BR112018070819A2 (pt) | peptídeos e composições farmacêuticas, nutracêuticas ou veterinárias para prevenção e/ou tratamento de queda de cabelo | |
CL2021000129A1 (es) | Apirasas solubilizadas, métodos y usos | |
BR112017014189A2 (pt) | terapia de câncer com um parvovirus combinado com bevacizumabe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |